Companies › Jazz Pharmaceuticals
11 active drug programs in 39 registered trials: 18 Phase 2, 14 Phase 1, 6 Phase 3, 1 Phase 4; Oncology, Neurology, Other, Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cannabidiol (GWP42003) Cannabinoid CB1 receptor negative allosteric modulator | CNR1 | Phase 4 | Lennox Gastaut Syndrome; Focal Seizures | Aug 2027 |
| Zanidatamab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Gastric Neoplasms; Metastatic HER2-positive Breast Cancer; Biliary Tract Cancer; Breast Cancer … | Dec 2026 |
| Xywav calcium, magnesium, potassium, and sodium oxybates solution | – | Phase 3 | Narcolepsy | Dec 2027 |
| Dordaviprone (ONC201) Imipridone; selective antagonist of dopamine receptors and trace amine-associated receptor | – | Phase 3 | H3 K27M | Jun 2028 |
| JZP3507 (ONC206) DRD2 agonist | DRD2 | Phase 2 | Meningioma; Advanced Pheochromocytoma and Paraganglioma; Central Nervous System Neoplasms | Mar 2027 |
| Lurbinectedin | – | Phase 2 | Extensive-stage Small-cell Lung Cancer; Refractory Ewing Sarcoma; Extensive-Stage Small Cell Lung Cancer; Lung Cancer … | Jan 2028 |
| JZP926 capsule | – | Phase 2 | Juvenile Myoclonic Epilepsy | Aug 2028 |
| JZP047 | – | Phase 1 | Healthy Participants | Nov 2026 |
| JZP269 | – | Phase 1 | Healthy Participants | Feb 2027 |
| JZP898 | – | Phase 1 | Advanced Solid Tumor | Nov 2027 |
| JZP815 MAPK pathway inhibitor | – | Phase 1 | Advanced Cancer | Apr 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07377539 | JZP047 | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT06497530 | Lurbinectedin | Phase 2 | Extensive-Stage Small Cell Lung Cancer | Oncology | Dec 2026 |
| NCT05099666 | Lurbinectedin | Phase 1 | Advanced Soft-tissue Sarcoma | Oncology | Dec 2026 |
| NCT05578326 | Lurbinectedin | Phase 2 | Lung Cancer | Oncology | Dec 2026 |
| NCT06695845 | Zanidatamab | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT06043427 | Zanidatamab | Phase 2 | Gastroesophageal Adenocarcinoma | Oncology | Dec 2026 |
| NCT05636111 | Lurbinectedin | Phase 1 | Ovarian Cancer | Oncology | Dec 2026 |
| NCT07813663 | JZP269 | Phase 1 | Healthy Participants | Other | Feb 2027 |
| NCT04541082 | JZP3507 (ONC206) | Phase 1 | Central Nervous System Neoplasms | Oncology | Mar 2027 |
| NCT05615818 | Zanidatamab | Phase 3 | Biliary Tract Neoplasms | Oncology | Jun 2027 |
| NCT05244239 | Lurbinectedin | Phase 1 | Extensive Stage Lung Small Cell Carcinoma | Oncology | Jul 2027 |
| NCT05044819 | Cannabidiol (GWP42003) | Phase 4 | Lennox Gastaut Syndrome | Gastroenterology | Aug 2027 |
| NCT06228066 | Lurbinectedin | Phase 2 | Small Cell Carcinoma of the Bladder | Oncology | Sep 2027 |
| NCT05152147 | Zanidatamab | Phase 3 | Gastric Neoplasms | Oncology | Sep 2027 |
| NCT07233239 | Cannabidiol (GWP42003) | Phase 1 | Focal Seizures | Neurology | Nov 2027 |
| NCT06108050 | JZP898 | Phase 1 | Advanced Solid Tumor | Oncology | Nov 2027 |
| NCT04802174 | Lurbinectedin | Phase 1 | SCLC | Oncology | Dec 2027 |
| NCT07296705 | Zanidatamab | Phase 2 | Muscle Invasive Bladder Cancer (MIBC) | Oncology | Dec 2027 |
| NCT07625280 | Xywav | Phase 3 | Narcolepsy | Neurology | Dec 2027 |
| NCT07102381 | Zanidatamab | Phase 2 | HER2-positive Breast Cancer | Oncology | Dec 2027 |
| NCT05734066 | Lurbinectedin | Phase 1 | Refractory Ewing Sarcoma | Oncology | Jan 2028 |
| NCT07192068 | Zanidatamab | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Mar 2028 |
| NCT05557045 | JZP815 | Phase 1 | Advanced Cancer | Oncology | Apr 2028 |
| NCT06435429 | Zanidatamab | Phase 3 | Metastatic HER2-positive Breast Cancer | Oncology | Apr 2028 |
| NCT07290985 | Zanidatamab | Phase 2 | Gastroesophageal Adenocarcinoma | Oncology | Jun 2028 |
| NCT05580562 | Dordaviprone (ONC201) | Phase 3 | H3 K27M | Oncology | Jun 2028 |
| NCT05918640 | Lurbinectedin | Phase 1 | Ewing Sarcoma | Oncology | Jul 2028 |
| NCT07723963 | JZP926 capsule | Phase 2 | Juvenile Myoclonic Epilepsy | Neurology | Aug 2028 |
| NCT07533942 | JZP3507 (ONC206) | Phase 2 | Meningioma | Oncology | Oct 2028 |
| NCT06282575 | Zanidatamab | Phase 3 | Biliary Tract Cancer | Oncology | Dec 2028 |
| NCT07282587 | JZP3507 (ONC206) | Phase 2 | Advanced Pheochromocytoma and Paraganglioma | Oncology | Dec 2028 |
| NCT07405476 | Zanidatamab | Phase 2 | Colon Carcinoma | Oncology | Dec 2028 |
| NCT05035836 | Zanidatamab | Phase 2 | Breast Cancer | Oncology | Dec 2028 |
| NCT07176312 | Zanidatamab | Phase 2 | Gastroesophageal Adenocarcinoma | Oncology | Mar 2029 |
| NCT07153055 | Lurbinectedin | Phase 1 | Small Cell Lung Cancer ( SCLC ) | Oncology | Apr 2029 |
| NCT07459634 | Lurbinectedin | Phase 2 | Extensive-stage Small-cell Lung Cancer | Oncology | Aug 2029 |
| NCT04607954 | Lurbinectedin | Phase 2 | Platinum-Resistant Lung Small Cell Carcinoma | Oncology | Sep 2030 |
| NCT07328425 | Lurbinectedin | Phase 2 | Desmoplastic Small Round Cell Tumor | Oncology | Oct 2030 |
| NCT05868226 | Zanidatamab | Phase 1 | HER2-positive Breast Cancer | Oncology | Dec 2030 |
Cash and short-term investments of $2.9bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Corcept Therapeutics DualityBio Exelixis Incyte Hutchmed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.